Clinical Trials Browser

Phase 3 × Has announcements × Everolimus × Clear all

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01713946 2018-11-07

EXIST-3

Phase 3 Completed

366 enrolled 38 charts 1 FDA

Tuberous Sclerosis Complex-associated Refractory Seizures